Where to buy Pitobrutinib/Pitobrutinib

Pirtobrutinib is a new generation of BTK inhibitors that have been included in the research and application scope of many authoritative institutions around the world. Unlike traditional BTK inhibitors, it blocks the BTK signaling pathway through non-covalent binding, so it can still work in people with drug-resistant mutations. This mechanism makes it an important option for the treatment of certain refractory B-cell malignancies, especially in patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL) and other related B-cell lymphomas. Due to the heterogeneity of hematological malignancies and the resistance of patients to previous BTK inhibitors, the emergence of pitubrutinib is regarded as a major breakthrough in this field.

Currently, the original drug Pitobrutinib has been approved for marketing in China, but it has not yet entered the medical insurance reimbursement list, which means that patients still have to bear high financial pressure at their own expense if they purchase the drug through formal domestic channels. The existing domestic sales version is usually packaged in 100 mg 14 tablets and 4 boards, with the price of each box being more than 40,000 yuan, which imposes a heavy financial burden on patients undergoing long-term treatment. At the same time, the original drugs in overseas markets are mainly divided into European and American versions, with specifications including 50mg 30 tablets and 100mg 60 tablets. The overall price is more expensive, with each box often selling for close to 100,000 yuan. The high price limits accessibility to many patients.

In order to improve drug affordability, generic versions of pitobrutinib have appeared in some countries or regions. Its ingredients are consistent with the original drug, and its efficacy and safety are highly consistent in theory. For example, the Laos pharmaceutical factory launches 50mg*30 tablets, with a price of more than 2,000 yuan per box (the price will fluctuate due to changes in international exchange rates). The launch of generic drugs has provided some patients with a more cost-effective choice, but they need to be extra cautious in purchasing channels and avoid obtaining drugs through informal channels to avoid the risk of counterfeit and substandard drugs.

Reference materials:https://go.drugbank.com/drugs/DB17472